Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...

The stock should perform well beyond 2030 thanks to its impressive innovative abilities. With a constellation of ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...

The global market for diabetes drugs used for treating obesity is expected to expand in Asia, as new players jostle with giants Eli Lilly and Novo ... competition will lead to more choices for ...